French biotech Osivax has raised 8m to fast-track development of its lead flu vaccine candidate and branch out to Belgium.
Author Archive for: UM
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 39 entries already.
Entries by Uta Mommert
It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (290m) in an upsized […]
Biophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to 10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases.
German biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics […]
German researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact.
Oncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.
Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the […]
It was a good day for Novartis: A second drug with huge selling potential has been approved for the US market. The FDA gave the go ahead for breast cancer […]
At BioEquity 2019, Spanish Bioindustry Association ASEBIO has given a sneak peek into its 2018 Annual Report, that each year describes the news and trends from the Spanish Biotech Sector.